Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Novakand Pharma AB
AB
Active
Org 5568068851
Nanna Svartz Väg 4, 171 65
Solna
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2010 · 16 years old
1-4 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Novakand Pharma AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
0M
0M
-1M
-1M
2020: 0M
0M
2020
2021: 0M
0M
2021
2022: 0M
0M
2022
2023: 0M
0M
2023
2024: 0M
0M
2024
EBITDA
SEK millions
0M
-20M
-40M
-61M
-81M
2020: -47M
-47M
2020
2021: -45M (+4% vs 2020)
-45M
+4%
2021
2022: -52M (-16% vs 2021)
-52M
-16%
2022
2023: -65M (-25% vs 2022)
-65M
-25%
2023
2024: -46M (+29% vs 2023)
-46M
+29%
2024
Income statement
SEK thousands
Item
2024
2023
2022
2021
2020
Revenue
0
0
0
0
90
Staff expenses
—
—
—
—
—
EBITDA
−46 161
−65 042
−51 934
−45 256
−46 681
Depreciation & amort.
—
—
—
—
—
EBIT
−46 161
−65 042
−51 934
−45 256
−46 681
Net financials
1 595
23
−934
−826
−1 073
Profit before tax
−44 566
−64 889
−52 367
−45 669
−47 664
Tax
−0
−0
−0
−0
−0
Net profit
−44 566
−64 889
−52 367
−45 669
−47 664
Balance sheet
SEK thousands
Item
2024
2023
2022
2021
2020
Total assets
66 911
65 643
120 494
132 096
82 242
Equity
62 300
47 665
107 059
122 567
72 296
Long-term debt
0
0
0
0
448
Short-term debt
4 611
17 978
13 434
9 529
9 498
Total debt
4 611
17 978
13 434
9 529
9 946
Financial ratios
5-year trend
EBITDA margin
<−999 %
This company
15,8 %
Market median
This company
Market median
>999% below market
2020
2024
Equity ratio
93,1 %
This company
38,2 %
Market median
This company
Market median
144% above market
2020
2024
Return on equity
−71,5 %
This company
18,4 %
Market median
This company
Market median
489% below market
2020
2024
Net profit margin
<−999 %
This company
8,1 %
Market median
This company
Market median
>999% below market
2020
2024
Asset turnover
0,00×
This company
1,12×
Market median
This company
Market median
100% below market
2020
2024
Debt / equity
0,07×
This company
0,62×
Market median
This company
Market median
89% below market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
More on Novakand Pharma AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
